News | January 17, 2026
Miach Orthopaedics’ BEAR implant gains FDA label claim for reduced arthritis risk
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
Experts caution that realizing AI’s potential requires careful management and risk mitigation
Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
NUFYMCO BLA has been approved by the USFDA
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
Subscribe To Our Newsletter & Stay Updated
